within Pharmacolibrary.Drugs.ATC.N;

model N04BC06
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 1.9999999999999998e-05,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.173,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00028333333333333335,
    Tlag           = 3600,            
    Vdp             = 0.468,
    k12             = 2.8,
    k21             = 2.8
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N04BC06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Cabergoline is a long-acting dopamine agonist used primarily to treat hyperprolactinemia (elevated prolactin levels), Parkinson's disease, and sometimes for conditions such as Cushing's disease. It is an orally active ergot derivative approved for use in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects after oral single dose administration.</p><h4>References</h4><ol><li><p>Del Dotto, P, &amp; Bonuccelli, U (2003). Clinical pharmacokinetics of cabergoline. <i>Clinical pharmacokinetics</i> 42(7) 633–645. DOI:<a href=\"https://doi.org/10.2165/00003088-200342070-00003\">10.2165/00003088-200342070-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12844325/\">https://pubmed.ncbi.nlm.nih.gov/12844325</a></p></li><li><p>Nakatsuka, A, et al., &amp; Nomoto, M (2006). Effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and in patients with Parkinson&#x27;s disease. <i>Journal of pharmacological sciences</i> 100(1) 59–64. DOI:<a href=\"https://doi.org/10.1254/jphs.fp0050711\">10.1254/jphs.fp0050711</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16410677/\">https://pubmed.ncbi.nlm.nih.gov/16410677</a></p></li><li><p>Andreotti, AC, et al., &amp; Pontiroli, AE (1995). Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers. <i>The Journal of clinical endocrinology and metabolism</i> 80(3) 841–845. DOI:<a href=\"https://doi.org/10.1210/jcem.80.3.7883840\">10.1210/jcem.80.3.7883840</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7883840/\">https://pubmed.ncbi.nlm.nih.gov/7883840</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N04BC06;
